CLINICAL TRIAL AGREEMENT

Made between San Mateo Medical Center, San Mateo County having a place of business at 222 West 39th Avenue, San Mateo, California 94403 ("Institution") with Joanne Imperial, MD, having a place of business at 222 West 39th Avenue, San Mateo, California 94403 (the "Investigator")and PPD Development, LP, a Texas limited partnership, having a place of business at 3151 South 17th Street, Wilmington, North Carolina 28412 ("PPD") representing the interests of **Idenix Pharmaceuticals, Inc.**, and its affiliates ("the Sponsor").

PROTOCOL NUMBER:	NV-02B-027
PROTOCOL TITLE:	An open-label, multicenter, randomized study of combination therapy with oral telbivudine plus adefovir dipivoxil versus adefovir dipivoxil alone in HBeAg-positive patien,ts with chronic hepatitis B who are lamivudine resistant
PROTOCOL DATE:	August 8, 2006
SPONSOR:	Idenix Pharmaceuticals, Inc.
INVESTIGATOR:	Joanne Imperial, MD

WHEREAS, the Investigator and Institution (hereafter, jointly, the "Site") are willing to conduct a clinical trial (the "Study"), in accordance with the above-referenced protocol and any subsequent amendments thereto (the "Protocol") and PPD requests the Site to undertake such Study;

NOW THEREFORE, the following is agreed:

1. PPD hereby appoints the Site to conduct the Study, and the Site agrees to ensure that the Site and the Site's employees, agents, and representatives will conduct the Study in accordance with the Protocol, the terms of this Clinical Trial Agreement, including the Terms and Conditions attached as Attachment A, the Payment Schedule and Budget attached as Attachment B, and any other attachments hereto, which all are incorporated by reference herein (the "Agreement"), good clinical practices, including ICH-GCP, and all applicable laws, regulations and guidelines.

2. Payments shall be made by PPD in accordance with the provisions set forth in Attachment B, with the last payment being made after the Site completes all of its obligations hereunder, and PPD has received all completed Case Report Forms ("CRFs") and all other Confidential Information as defined in Attachment A, Article 2 (Confidential and Proprietary Information). The Site will act as an independent contractor, and PPD shall not be responsible for any employee benefits, pensions, workers' compensation, withholding, or employment-related or other taxes as to the Site or any of its employees, agents or representatives. The Site hereby acknowledges and agrees that payments due under this Agreement are pass-through payments from Sponsor and that PPD shall have no payment obligations hereunder until such time as said payments are received

by PPD from Sponsor. The Site acknowledges and agrees that Investigator's independent judgment with respect to Investigator's advice to and care of each subject is not affected by the compensation Site receives hereunder. The parties agree that the payee designated below is the proper payee for this Agreement, and that payments under this Agreement will be made only to the following payee (the "Payee"):

PAYEE NAME:	San Mateo Medical Center
PAYEE ADDRESS: (Must be full street address – No P.O. boxes allowed)	222 West 39th Avenue
	San Mateo, CA 94403
TAX ID NUMBER	94-6000532

If the Payee is in the U.S., the Payee's 9 Digit Tax Identification Number and SSN/EIN designation will be required before any payments can be made under this Agreement.

Site will have 30 days from the receipt of final payment to dispute any payment discrepancies during the course of the Study. The parties acknowledge that the designated Payee is authorized to receive all of the payments for the services performed under this Agreement. If the Investigator is not the Payee, then the Payee's obligation to reimburse the Investigator will be determined by a separate agreement between Investigator and Payee. **Investigator acknowledges that if Investigator is not the Payee, PPD will not pay Investigator even if the Payee fails to reimburse Investigator.**

3. This Agreement will become effective on the date on which it is last signed by the parties. In the event of a conflict between the Protocol and this Agreement, the terms of the Protocol will govern.

4. The Parties hereby represent that each of their respective signatories is duly authorized and that each Party relies on the authenticity of each signature to be that of a duly authorized representative.

[Signature on the following page]

ACKNOWLEDGED AND AGREED BY

PPD DEVELOPMENT, LP
BY: PPD GP, LLC
ITS GENERAL PARTNER

By: _____

Date: _____

ACKNOWLEDGED AND AGREED BY THE INVESTIGATOR:

By: _____
Joanne Imperial, MD

Date: 10/2/06

ACKNOWLEDGED AND AGREED BY THE INSTITUTION:

By: _____
Jerry Hill

Title: President, Board of Supervisors
(must be authorized to sign on Institution's behalf)
San Mateo County

Date: _____

ATTEST: _____
Clerk of Said Board

DATE: _____

ATTACHMENT A
TERMS AND CONDITIONS

1) Conduct of the Study. The parties to the Agreement agree that the Study will be performed in strict accordance with the Protocol, applicable federal, state, and local laws, regulations and guidelines, and good clinical practices ("GCPs"). The Site shall insure that the Investigator shall maintain all clinical data and shall prepare and review all case report forms ("CRFs") to ensure their accuracy, completeness and legibility, shall review and understand the information in the Investigator Brochure, shall ensure that all written informed consent requirements are met and that the consent obtained from Study subjects shall comply with applicable laws and regulations addressing the disclosure of private health information, and shall ensure that all required reviews and approvals by applicable regulatory authorities and Institutional Review Boards ("IRBs") or Independent Ethics Committees ("IECs") are obtained. The Site shall promptly and fully produce all data, records and information relating to the Study to PPD, the Sponsor, and their representatives during normal business hours, and shall assist them in promptly resolving any questions and in performing audits or reviews of original subject records, reports, or data sources. The Site agrees to cooperate with the representatives of international and national regulatory authorities and agencies, PPD and Sponsor who visit the Site.

The Site shall use the drugs being tested (the "Investigational Product"), and any comparator products provided in connection with the Study, solely for the purpose of properly completing the Study in accordance with the Protocol and shall maintain all Investigational Product and any comparator products in a locked, secured area at all times. Upon completion or termination of the Study, the Site shall return to PPD or Sponsor all unused Investigational Product, comparator products, equipment, and materials and all Confidential Information (as defined below), provided however that the Site may retain one copy of all documents for archival purposes for use in connection with regulatory requirements and as evidence of Site's performance of its obligations hereunder.

All correspondence with an IRB or IEC and PPD and all records relating to the trial, including copies of the CRFs, should be maintained until at least 2 years after the last approval of a marketing application in an ICH region and until there are no pending or contemplated marketing applications in an ICH region or at least 2 years have elapsed since the formal discontinuation of clinical development of the Investigational Product (whichever comes later). Either PPD or the Sponsor must be informed in writing of any change of address or relocation of the trial files during this period. It is the responsibility of the Sponsor to inform the Site as to when these documents no longer need to be retained.

The Site will attempt to enroll a minimum of eight (8) evaluable subjects in the Study, to be conducted in accordance with the Protocol. An evaluable subject means a subject who meets all inclusion/exclusion criteria to enroll in the Study, has provided written informed consent and does not have significant Study Protocol violations that would cause the exclusion of his/her data from analysis. Recruitment is intended to begin in September 2006 and be completed by March 2007, with all Baseline assessments being completed by March 2007. Recruitment will end upon enrollment of approximately one hundred and fifty (150) subjects among all Study sites. Sponsor

retains the right to change the number of subjects to be entered and the start and recruitment completion dates. Notice will be provided to the Site in writing of any change in the recruitment plan. If the Site does not enroll one subject within four (4) months of Site's Site Initiation Visit, PPD and the Sponsor have the right to close the Site due to inactivity. Furthermore, if at any time during the course of the Study the Site has not reached its own enrollment target but the overall target of the Study has been reached, the Site will upon written request by PPD immediately stop recruitment. PPD will use reasonable commercial efforts to provide trial supplies in order to facilitate the agreed time scales.

2) Confidential and Proprietary Information. All information (including, but not limited to, the Protocol, Investigator Brochure, CRFs and any other Study-related documents, descriptions, data, intellectual property and instructions), and materials (including, but not limited to, the Investigational Product and comparator products), provided to the Site by PPD, Sponsor, or their agents (whether verbal, written, electronic or tangible form), and all results, data, reports and information relating to the Study or its progress (hereinafter, the "Confidential Information") shall be the sole and exclusive property of Sponsor. The Site shall keep the Confidential Information strictly confidential, shall use it only in connection with the legitimate purposes of this Agreement, and shall disclose it only to its employees, agents and representatives involved in conducting the Study who have a need to know it and are obligated to keep the same in confidence. The Site agrees to be responsible for any unauthorized disclosure or use of the Confidential Information by its employees, agents and representatives. These confidentiality obligations shall continue until ten (10) years after completion of the Study, but shall not apply to Confidential Information to the extent that it: a) is or becomes publicly available through no fault of the Site; b) is disclosed to the Site by a third party not subject to any obligation of confidence; c) must be disclosed to IRBs, IECs, or applicable regulatory authorities; d) must be included in any subject's informed consent form; e) is published in accordance with Article 3 herein; or, f) is required to be disclosed by applicable law, provided that Site limits such disclosure to the fullest extent possible and that Sponsor is notified as soon as possible of any such requirement to allow Sponsor to seek a protective order or other modifications to the requirement. Each party agrees to comply with any applicable patient privacy or data protection laws and regulations.

The respective existing inventions, know-how and technologies of Sponsor, PPD, or the Site are their separate property and are not affected by this Agreement. Sponsor shall have sole and exclusive ownership of any inventions, improvements, discoveries or reductions to practice, whether patentable or not, arising directly or indirectly and whether in whole or in part from the Confidential Information or arising as a result of the Study (collectively, "Inventions"). The Site agrees to promptly and fully disclose to Sponsor in writing any such Inventions made by Investigator(s), Institution, or its employees, agents and representatives, and to assign, or cause its Investigator(s), employees, agents or representatives to assign, without charge to Sponsor, all of such rights, title and interest in and to such Inventions to Sponsor or its nominee. The Site will use reasonable efforts to assist Sponsor, at Sponsor's expense, to execute any documents and give any testimony necessary for Sponsor to obtain patents in any country or to otherwise protect Sponsor's interests in such Inventions. The Site shall have exclusive ownership of any inventions or discoveries conceived by the Site during

the time that the Study is taking place that do not arise in whole or in part from the Study or any Confidential Information, but the Site shall offer the Sponsor the right of first refusal as to any sales or licenses of such inventions or discoveries. The obligations of this Section 2 shall survive termination of this Agreement.

3) Publication. Any formal presentation or publication of data collected as a result of this Study will be considered as a joint presentation or publication by the Investigator(s) and the Sponsor. As is customary for multi-center trials, publication or presentation of data by individual institutions or investigators will not be allowed prior to the publication of the principal Study abstract(s) and manuscript(s), without the explicit written permission of Sponsor. Site acknowledges that Sponsor will determine authorship of the principal Study manuscript(s) in conjunction with the investigator(s). All investigators contributing at least one evaluable patient to the Study will be considered as co-authors for the principal Study manuscript(s). For such manuscript(s), masthead roles for Investigators will be determined based on patient enrollment and scientific contributions to the Study.

Subsequent to the publication of the principal Study manuscripts(s) and abstracts(s), Institution and Investigator may, consistent with academic and scientific standards, publish or present the results of work performed in accordance with the Study, provided that any proposed publication, presentation, abstract, submission or disclosure (collectively hereinafter "Proposed Publication") is first reviewed and commented upon by Sponsor prior to submission for publication or presentation. At least sixty (60) days prior to submitting or presenting a Proposed Publication to a publisher, reviewer, or other outside persons, the Institution or Investigator shall provide to Sponsor a copy of any such Proposed Publication. If the Sponsor requests, the Institution or Investigator shall remove any Confidential Information (other than Study results) prior to submitting or presenting the Proposed Publication. At the request of Sponsor, each of the Institution and Investigator agree to withhold submission of a Proposed Publication for an additional period of up to sixty (60) days after receipt of Sponsor's comments, in order to allow the Sponsor to file patent applications relating to an Invention (as defined in this Agreement) or otherwise to seek protection of information to be published or otherwise disclosed. No party hereto shall use the other party's name, or Sponsor's name, in connection with any advertising, publicity or promotion without prior written consent. The obligations of this Section 3 shall survive termination of this Agreement.

4) Inspection and Debarment. When given reasonable notice, the Site agrees to allow authorized PPD, Sponsor or regulatory authority personnel direct access to the Site and the Site's records relating to the Study, including subject medical records, for monitoring, auditing, and inspection purposes. The Site shall immediately notify PPD of, and provide PPD copies of, any inquiries, correspondence or communications to or from any governmental or regulatory authority relating to the Study, including, but not limited to, requests for inspection of the Site's facilities, and the Site shall permit PPD and Sponsor to attend any such inspections. The Site will make reasonable efforts to separate, and not disclose, all Confidential Information that is not required to be disclosed during such inspections. The Site shall maintain essential Study documents for the time and in the manner specified by current good clinical practice guidelines, local laws, the Protocol and any other Sponsor requirements and shall take measures to prevent accidental or premature destruction of these documents. The Site represents

and warrants that neither it, nor any of its employees, agents or representatives performing the Study under its direction, has been debarred, disqualified or banned from conducting clinical trials or is under investigation by any regulatory authority for debarment or any similar regulatory action in any country, and the Site shall notify PPD immediately if any such investigation, disqualification, debarment, or ban occurs.

Site also agrees for the purposes of Site monitoring to maintain adequate records with respect to subject identification, clinical observations, laboratory tests and drug receipt and disposition. If any source data are kept on computer files only, Site will make print-outs of all patients' data relevant for the trial for the purpose of source data verification. These print-outs will be signed and dated by Site and retained as source documents. Site will allow direct access to source documents and other patient records needed for monitoring, audit and inspection purposes. Site agrees to return or destroy unused investigational products, devices and trial-related materials at the end of the trial, or at intervals, as directed by PPD/the Sponsor.

5) Termination. PPD may terminate this Agreement effective immediately upon written notice. The Site may terminate upon written notice if circumstances beyond the Site's reasonable control prevent the Site from completing the Study, or if the Site reasonably determines that it is unsafe to continue the Study. Upon receipt of notice of termination, the Site shall follow the PPD specified termination procedures, ensure that any required subject follow-up procedures are completed, and make all reasonable efforts to minimize further costs. PPD shall make a final payment for visits or milestones properly performed pursuant to this Agreement in the amounts specified in the Payment Schedule; provided, however, that ten percent (10%) of this final payment will be withheld until final acceptance by Sponsor of all subject CRFs and all data clarifications issued and satisfaction of all other applicable conditions set forth in the Agreement. To the extent that payments already advanced by PPD to Site exceed the payment due and owing upon termination, the Site will promptly refund such unearned payment to PPD. Neither PPD nor Sponsor shall be responsible to the Site for any lost profits, lost opportunities, or other consequential damages. If a material breach of this Agreement appears to have occurred and termination may be required, then, subject to patient safety, PPD may suspend performance of all or part of this Agreement, including, but not limited to, subject enrollment.

6) Claims and Disclaimers. The Site shall promptly notify PPD and Sponsor in writing of any claim of illness or injury actually or allegedly due to an adverse reaction to the Investigational Product or other serious adverse event or to a Study procedure and allow Sponsor to handle such claim (including settlement negotiations, if any), and shall cooperate fully with Sponsor in its handling of the claim. **PPD expressly disclaims any liability in connection with the Investigational Product, including any liability for any product claim arising out of a condition caused by or allegedly caused by the administration of such product**. Neither PPD nor Sponsor, nor their successors in interest, affiliates, shareholders, directors, officers, employees, agents or representatives will be responsible for, and the Site agrees, to the extent allowed by law, to indemnify and hold them harmless from, any loss, claim, or demand arising from any injuries or damages resulting from the Site's negligence or willful misconduct, failure to adhere to the Protocol or applicable laws, regulations, guidelines and written

instructions, failure to obtain proper informed consent, unauthorized warranties, or breach of this Agreement.

If the Site is in the U.S., both Institution and Investigator shall maintain professional liability insurance coverage with limits of not less than one million dollars ($1,000,000 USD) per occurrence and three million dollars ($3,000,000 USD) aggregate throughout the term of this Study if the policy is an occurrence policy, and for an additional five (5) years after completion of the Study if such insurance is a claims-made policy, and will provide, upon request, a certificate of insurance. If the Site is in Canada, it shall obtain, and maintain in good standing, membership with the Canadian Medical Protective Association. If the Site is outside of the U.S. or Canada, it shall maintain a commercially reasonable level of insurance, and, upon signature of this agreement, shall provide a certificate of insurance to PPD. No payments shall become due for Services rendered hereunder until Site provides PPD with a complete and accurate W-9 tax form, or if outside the U.S., the applicable and commercially standard tax form, and a certificate of insurance evidencing insurance coverage in compliance with Site's obligations herein.

7) Financial Disclosure. If PPD or Sponsor provides financial disclosure forms to the Site pursuant to U.S. regulatory, including FDA, requirements, then the Site agrees that, for each listed or identified Investigator or subinvestigator who is directly involved in the treatment or evaluation of research subjects, it shall promptly return to PPD a financial disclosure form that has been completed and signed by such Investigator or subinvestigator, which shall disclose any applicable interests held by those Investigators or subinvestigators or their spouses or dependent children. PPD may withhold payments if it does not receive a completed form from each such Investigator and subinvestigator. The Site shall ensure that all such forms are promptly updated as needed to maintain their accuracy and completeness during the Study and for one year after its completion. The Site agrees that the completed forms may be subject to review by governmental or regulatory agencies, Sponsor, PPD, and their agents, and the Site consents to such review. The Site further consents to the transfer of its financial disclosure data to the U.S. if the Site is outside of the U.S., even though data protection may not be as developed as in the Site's own country.

8) Shipping of Dangerous Goods and Infectious Materials. The shipment of dangerous goods and infectious materials (including infectious subject specimens) is subject to local, national, and international laws and regulations. The Site is responsible for ensuring that each individual who packages or handles any dangerous goods or infectious materials for shipping from the Site complies with all applicable laws and regulations (including, but not limited to, U.S. Federal Aviation Administration regulations if the materials will be shipped in the U.S.) and obtains and documents all training required by such laws and regulations. Any information provided by PPD concerning transportation of dangerous goods or infectious materials is not intended to be, and should not be considered as, training in the packaging or handling of dangerous goods or infectious materials.

9) Additional Contractual Provisions. The Site shall be an independent contractor and shall not be considered the partner, agent, employee, or representative of PPD or Sponsor. This Agreement, including these Terms and Conditions, and any other

attachments constitutes the sole and complete agreement between the parties and replaces all other written and oral agreements relating to the Study. This Agreement shall be effective upon the date it is signed by all the parties and shall continue until completed or terminated. No amendments or modifications to this Agreement shall be valid unless in writing and signed by all the parties. Failure to enforce any term of this Agreement shall not constitute a waiver of such term. If any part of this Agreement is found to be unenforceable, the rest of this Agreement will remain in effect, and the unenforceable provision shall be deemed replaced by a provision which is valid and enforceable and corresponds most closely to the intent of the parties as evidenced by the original provision. This Agreement shall be binding upon the parties and their successors and assigns. The Site shall not assign or transfer any rights or obligations under this Agreement without the written consent of PPD. Upon Sponsor's request, PPD may assign this Agreement to Sponsor or to a third party, and thereafter PPD shall not have any obligations or liabilities under this Agreement, and the Site hereby consents to such an assignment. Site will be given prompt notice of such assignment by the assignee. The terms of this Agreement that contain obligations or rights that extend beyond the completion of the Study shall survive termination or completion of this Agreement. This Agreement shall be interpreted under the laws of the state of North Carolina, U.S.A., without regard to the conflict of laws provisions thereof.

ATTACHMENT B

Idenix Pharmaceuticals, Inc.
Protocol #NV-02B-027
BUDGET AND PAYMENT SCHEDULE

A. PAYMENT TERMS:

PPD will reimburse the Payee quarterly (January, April, July and October), on a completed visit per patient basis in accordance with the attached budget. Ninety percent (90%) of each payment due will be made based upon the prior quarter's enrollment data confirmed by full data entry of the patient Case Report Forms (CRFs) received from the Site supporting patient visitation. The balance of monies earned, up to Ten Percent (10%), will be pro-rated upon verification of actual patient visits, and will be paid by PPD to the Payee upon final acceptance by Sponsor of all CRFs pages, all data clarifications issued, the receipt and approval of any outstanding regulatory documents as required by PPD and/or Sponsor, the return of all unused Investigational Product, comparator products, other supplies and Confidential Information to PPD, and upon satisfaction of all other applicable conditions set forth in the Agreement. Where the compensation in this agreement is indicated in a currency other than the local country currency such currency will be converted to the local country currency for invoicing and payment purposes at the spot rate quoted by the Wall Street Journal on the date of payment.

Disqualifying Protocol violations are not payable under this Agreement.

B. ADVANCE PAYMENT:

Upon completion and receipt by PPD of all **original** contractual and regulatory documentation, PPD will pre-pay a portion of the monies that Site will be entitled, under Section A of this Budget and Payment Schedule, to receive as it performs patient activities covered by such Section (the "Advance"). Consequently, as it performs these patient activities, Site will not receive payment for them from PPD under such Section, but will instead incrementally earn the Advance. Once Site has earned the entire Advance, payments from PPD under such Section will resume for subsequent patient activities covered by such Section that are performed by Site. If, upon completion or termination of this Agreement, the amount of the Advance exceeds the amount that Site is entitled to receive under such Section for all the patient activities covered by such Section that it performed up to that time, then Site shall promptly remit the difference to PPD. The amount of the Advance is two thousand dollars and no cents ($2,000.00 USD).

Any expense or cost incurred by Site in performing this Agreement that is not specifically designated as reimbursable by PPD or Sponsor under the Agreement (including this Budget and Payment Schedule) is Site's sole responsibility.

C. SCREEN FAILURES:

Screen failures will not be reimbursed for this Study.

D. DISCONTINUED OR EARLY TERMINATION PAYMENTS:

Reimbursement for discontinued or early termination subjects will be prorated based on the number of confirmed completed visits.

E. ORIGINAL INVOICES:

Original Invoices pertaining to this Study for the following items must be submitted to PPD for reimbursement at the following address:

PPD Development, LP
Attn: King Lo, Clinical Team Manager
3151 South 17th Street
Wilmington, NC 28412

Please note that invoices will not be processed unless they reference the Sponsor name, Protocol number and Investigator. After receipt and verification, reimbursement for invoices will be included with the next regularly scheduled payment for patient activity.

- **Patient Recruitment/Advertising**

Advertising will not be reimbursed for this study.

- **Institutional Review Board/Independent Ethics Committee (IRB/EC) Payments**

IRB/EC costs will be reimbursed on a pass-through basis and are not included in the attached budget. Any subsequent re-submissions or renewals, upon approval by PPD and Sponsor, will be reimbursed upon receipt of appropriate documentation.

NO OTHER ADDITIONAL FUNDING REQUESTS WILL BE CONSIDERED.

The Budget is as follows:

BUDGET

NV-02B-027 ESTIMATED iNVESTIGATOR GRANT - Original																					
STUDY PHASE/WEEK	SCREENING	Day 1	Week 2	Week 4	Week 8	Week 12	Week 16	Week 24	Week 36	Week 48	Week 60	Week 72	Week 84	Week 96	F/U Week 4	F/U Week 8	F/U Week 12	F/U Week 16	TOTAL	Early Term (if required)	Unscheduled visit
VISIT	1	2	5	6	7	8	9	11	14	16	17				18	19	20	21			
PROCEDURE:																					
Informed Consent	100.00																		100.00		
Medical History	150.00																		150.00		
Physical Exam	100.00							100.00		100.00				100.00					400.00	100.00	
*Symptom directed PE if required		50.00	50.00	50.00	50.00	50.00	50.00		50.00		50.00	50.00	50.00		50.00	50.00	50.00	100.00	750.00		50.00
Lab Draws/Sample Processing	100.00	50.00	50.00	50.00	50.00	50.00	50.00	50.00	50.00	50.00	50.00	50.00	50.00	50.00	50.00	50.00	50.00	50.00	950.00	50.00	50.00
Urine Collection	10.00	10.00				10.00		10.00		10.00		10.00		10.00		10.00		10.00	90.00	10.00	
Professional Fees (including Assessment,Clinic visit,data management)	225.00	175.00	175.00	175.00	175.00	175.00	175.00	175.00	175.00	175.00	175.00	175.00	175.00	175.00	175.00	175.00	175.00	175.00	3,200.00	175.00	100.00
Estimated Patient Reimbursement (travel and parking)		25.00	25.00	25.00	25.00	25.00	25.00	25.00	25.00	25.00	25.00	25.00	25.00	25.00	25.00	25.00	25.00	25.00	425.00	25.00	
TOTAL DIRECT FEES	685.00	310.00	300.00	300.00	300.00	310.00	300.00	360.00	300.00	360.00	300.00	310.00	300.00	360.00	300.00	310.00	300.00	360.00	6,065.00	360.00	200.00
OVERHEAD (20%)	137.00	62.00	60.00	60.00	60.00	62.00	60.00	72.00	60.00	72.00	60.00	62.00	60.00	72.00	60.00	62.00	60.00	72.00	1,213.00	72.00	40.00
TOTAL COSTS PER PATIENT	822.00	372.00	360.00	360.00	360.00	372.00	360.00	432.00	360.00	432.00	360.00	372.00	360.00	432.00	360.00	372.00	360.00	432.00	7,278.00	432.00	240.00
NOTES:																					
1. IRB fees will be reimbursed upon receipt of invoice																					
2. *Payment for symptom directed PE is only reimbursed if PE conducted																					
3. $2000 will be paid upon execution of contract for study start-up (including pharmacy start-up and IRB preparation). Start-up fee is refundable if no patients enrolled in study.																					
4. Screen failures will not be reimbursed																					